Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MAX | P61244 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730399 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL2457536 | 0.98 | ALDH1A1 (0.52) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL26906432 | 0.96 | ALDH1A1 (0.50) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL28769561 | 0.89 | ALDH1A1 (0.43) | ALDH1A1HPGDGLAMAPTACHE | |
| Formic Acid SCHEMBL28768466 | 0.89 | ALDH1A1 (0.43) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL26749714 | 0.88 | ALDH1A1 (0.62) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL29749614 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL21296280 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDGLAMAPTACHE | |
| Fluorene SCHEMBL28796281 | 0.84 | MAPT (0.57) | ALDH1A1HPGDGLAMAPTACHE | |
| SCHEMBL31011005 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HPGDGLAMAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790875-B1 | N-HETEROARYLENE COMPOUNDS WITH LOW LUMO ENERGIES | NOVALED GMBH (DE) | 2024-07-03 | — | — | EP | claimed |
| EP-3567039-B1 | N-HETEROARYLENE COMPOUNDS WITH LOW LUMO ENERGIES | NOVALED GMBH (DE) | 2024-05-08 | — | — | EP | claimed |
| EP-3425692-B1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING AN ELECTRON INJECTION LAYER WITH ZERO-VALENT METAL | NOVALED GMBH (DE) | 2023-04-05 | — | — | EP | claimed |
| EP-3824500-B1 | COMPOUND AND ORGANIC SEMICONDUCTING LAYER, ORGANIC ELECTRONIC DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE COMPRISING THE SAME | NOVALED GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025125148-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY DEVICE | NOVALED GMBH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-12108664-B2 | Compound and organic semiconducting layer, organic electronic device, display device and lighting device comprising the same | NOVALED GMBH (DE) | 2024-10-01 | — | — | US | disclosed |
| EP-3598515-B1 | COMPOUND AND ORGANIC SEMICONDUCTING LAYER, ORGANIC ELECTRONIC DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE COMPRISING THE SAME | NOVALED GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| EP-3790875-B1 | N-HETEROARYLENE COMPOUNDS WITH LOW LUMO ENERGIES | NOVALED GMBH (DE) | 2024-07-03 | — | — | EP | disclosed |
| US-20230339862-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-26 | — | — | US | disclosed |
| EP-4211115-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-4211115-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-07-19 | — | — | EP | disclosed |
| EP-3425692-B1 | ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING AN ELECTRON INJECTION LAYER WITH ZERO-VALENT METAL | NOVALED GMBH (DE) | 2023-04-05 | — | — | EP | disclosed |
| WO-2022053704-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022053704-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12108664-B2 | Compound and organic semiconducting layer, organic electronic device, display device and lighting device comprising the same | OCIAD1, OCIAD2, AOX1 | ALDH1A1 41/4885HPGD 2839/4885GLA 2429/4885 |
| US-20230339862-A1 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | DDX41, DDX42, EWSR1 | ALDH1A1 2436/4885HPGD 2792/4885GLA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.